GenEdit announced a multiyear collaboration and license agreement with Genentech.
GenEdit, a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group. The companies will employ GenEdit’s NanoGalaxy platform to discover and develop…